SPOTLIGHT -
Recapping the FDA's Cancer Drug Approvals From The Winter
Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.
Earlier Use Of Jakafi Leads To Improved Symptoms And Higher Survival In Myelofibrosis Patients
Treating myelofibrosis with Jakafi earlier has shown promise in improving both survival and symptom burden
Supplemental BLA Accepted For Melanoma Treatment
The FDA agreed to review a supplemental Biologics License Application for Opdivo to treat stage 2B or C, fully resected melanoma.
